Pakistan’s pharmaceutical sector has achieved a major recovery, bringing back more than 80% of the medicines that had disappeared from shelves over the past two years. According to the Pakistan Pharmaceutical Manufacturers Association (PPMA), around 160 out of 200 previously unavailable drugs are now back in production and retail markets.
The shortage began when production costs exceeded retail prices, forcing companies to halt manufacturing. This crisis affected life-saving medicines for tuberculosis, cancer, diabetes, cardiovascular conditions, and psychiatric treatments. Patients and healthcare providers faced severe challenges during this period.
The turning point came in February 2024, when the government deregulated pricing for non-essential medicines. This allowed pharmaceutical firms to set retail prices independently, making production viable again. At the same time, the government raised prices of about 100 essential medicines to ensure they remained above production costs.
Industry leaders highlight that deregulation did not lead to uncontrolled price hikes. Instead, it fostered competition among manufacturers, stabilized supply chains, and eliminated fake or black-market drugs. As a result, patients now have greater access to genuine medicines at affordable prices.
The revival also boosted exports. Pakistan’s pharmaceutical exports rose by 34% in fiscal year 2025, reaching $457 million—a two-decade high. Locally produced medicines secured fifth place among the fastest-growing export categories. With nine companies already certified by international bodies like WHO and PIC/S, and another dozen preparing for certification, Pakistan is poised to expand into high-value markets in Europe and North America.
Industry experts note that raw material imports remain a challenge, especially after political tensions halted supplies from India. However, firms are diversifying sources and investing heavily in production expansion. With around 700 pharmaceutical companies, including 10 multinationals, the sector is showing resilience and growth.
This recovery marks a significant milestone for Pakistan’s healthcare system. By restoring access to critical medicines and strengthening exports, the pharmaceutical industry is not only meeting domestic needs but also positioning itself as a competitive player in global markets.
+ There are no comments
Add yours